儿童矮小症应用生长激素的长期安全性  

Long-term safety of recombinant human growth hormone treatment in children

作　　者：张晓洁[1] 沈永年[1] 

机构地区：[1]上海交通大学医学院附属上海儿童医学中心,上海200127

出　　处：《临床儿科杂志》2011年第8期789-792,共4页Journal of Clinical Pediatrics

摘　　要：生长激素(GH)于1956年首先从人垂体中分离出,其生物化学结构直到1972年才阐明。重组DNA技术和基因工程方法,实现了人生长激素(hGH)的大规模生产,使hGH普遍利用成为可能。文章综述生长激素在儿童生长激素缺乏症、慢性肾功能不全、Turner综合征、Prader-Willi综合征、小于胎龄儿持续矮小、特发性矮小、矮小同源异型盒基因(SHOX)缺陷疾病中的应用方法和安全性。提示重组hGH用于儿童的安全性令人满意,但也需注意有潜在风险的特殊群体。Growth hormone（GH）was isolated firstly from the human pituitary gland in 1956,but its biochemical structure was not elucidated until 1972.The first recombinant human GH（rhGH）was developed by a process called recombinant DNA technology.This is currently the most common method used to synthesize rhGH,which lead to full scale operation coming true.Long-term safety of using rhGH in children with growth hormone deficiency,chronic renal insufficiency,Turner syndrome,Prader-Willi syndrome,small for gestational age,idiopathic short stature,short stature homeobox gene deficiency is reviewed accordingly.Although a favorable overall profile of using rhGH has been confirmed,specific populations at potential risk should be aware of.

关 键 词：生长激素 矮小症 安全性 

分 类 号：R725.8[医药卫生—儿科]